News

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara® (ustekinumab) and Humira® (adalimumab), bringing the total number of Stelara® interchangeables to four, plus an additional biosimilar (Sandoz / Samsung Bioepis’s Pyzchiva® (ustekinumab-ttwe) that has provisionally been approved as interchangeable, and the total Humira® interchangeables to six.

These approvals bring the total interchangeable biosimilar approvals in the US to 22, 15 of which have been approved in 2024-25.  The increased number of interchangeable approvals has come after the FDA has sought to lessen the burden of proving interchangeability, including revising its interchangeability guidance in June 2024 to eliminate the switching study requirement for many drugs (previously reported FDA Revises Guidance on Switching Studies for Biosimilar Interchangeability).

On May 5, 2025, Alvotech and Teva announced the FDA-approval of Selarsdi™ (ustekinumab-aekn) as interchangeable with Stelara®. Selarsdi™ was originally approved as biosimilar in April 2024 and launched in February 2025.  On May 19, 2025, Fresenius Kabi and Formycon announced Otulfi®’s (ustekinumab-aauz) interchangeable approval. Otulfi® was originally approved as biosimilar to Stelara® in September 2024 and launched in March 2025.  On May 22, 2025, the FDA approved Bio-Thera and Hikma’s Starjemza® (ustekinumab-hmny) as an interchangeable biosimilar of Stelara®.

On May 20, 2025, the FDA expanded its interchangeability designation for Celltrion’s Yuflyma® (adalimumab-aaty) to all approved dosage forms and strengths, and it is now fully interchangeable with Humira®Yuflyma® was initially approved in May 2023 as a high-concentration interchangeable for prefilled 20 and 80mg syringes.  The new interchangeability designation added the 40mg syringe and 40 and 80mg autoinjector presentations.

On May 27, 2025, the FDA expanded the interchangeability designation for Samsung Bioepis and Organon’s Hadlima™ (adalimumab-bwwd)Hadlima™ was originally approved as a low-concentration Humira® biosimilar in July 2019 and received an interchangeability designation for low-concentration 40mg/0.8mL prefilled syringes and single dose vials in June 2024.  It was approved in a high-concentration formulation in August 2022, and it is now fully interchangeable with all of Humira®’s presentations.

For more information on these and other biosimilars, please visit BiologicsHQ.

 

____________________________________

The author would like to thank April Breyer Menon for her contributions to this article.


    Methodology

    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

    Disclaimer

    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates

      captcha